A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluovouracil/folinic acid in patients with advanced gastric cancer

Anti-Cancer Drugs

Volumn 8, Issue 4, 1997, Pages 396-399

  Bokemeyer, Carsten ^c   Lampe, Christine S ^c   Clemens, Michael R ^a   Hartmann, Jörg T ^c   Quietzsch, Detlev ^b   Forkmann, Lutz ^b   Kollmannsberger, Christian ^c   Kanz, Lothar ^c  

^a Krankenanstalt Mutterhaus ^*  (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

5 Fluorouracil; Advanced gastric cancer; Folinic acid; Paclitaxel; Phase II trial

Indexed keywords

FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; VOMITING;

EID: 0031001109     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199704000-00014     Document Type: Article

References (13)

1. Kremer B, Henne-Bruns D, Weh HJ, et al. Advanced gastric cancer: a new combined surgical and oncological approach. Hepatogastroenterology 1989; 36: 23-6.
2. Vanhoefer U, Harstrick A, Wilke H, et al. Taxol in combination with cisplatin, etoposide and 5-FU in gastric cancer cell lines. Proc Am Ass Cancer Res 1994; 35: 508 (abstr).
3. Chang YF, Li LL, Wu CW, et al. Paclitaxel-induced apoptosis in human gastric carcinoma cell-lines. Cancer 1996; 77: 14-8.
4. Murad AM, Nogueira da Costa R, Tinoco LA, et al. Paclitaxel (T) plus 5-fluorouracil (5-FU): A very active regimen for advanced gastric cancer (ACG)? Preliminary results of a phase II trial. Ann Oncol 1996; 7(suppl 5): 234 (abstr).
5. Klaassen U, Wilke H, Seeber S. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Semin Oncol 1996; 23(5 suppl 11): 32-7.
6. Treat J, Falchuk SC, Woolley PV, et al. Therapy of advanced gastric carcinoma. The Georgetown Lombardi Cancer Center experience. Am J Clin Oncol 1989; 12: 162-8.
7. Kano Y, Akutsu M, Tsunoda S, et al. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 1996; 74: 704-10.
8. Safran H, King T, Choy H, et al. Phase I study of paclitaxel and concurrent radiation for locally advanced gastric and pancreatic cancer. Proc Am Soc Clin Oncol 1996; 15: 442 (abstr).
9. Ajani JA, Ilson DH, Bhalla K, et al. Taxol, cisplatin and 5-FU: a multi-institutional phase II study in patients with carcinoma of the esophagus. Proc Am Soc Clin Oncol 1995; 14: 489 (abstr).
10. Ajani JA, Ilson DH, Kelsen DP. The activity of paclitaxel in gastrointestinal tumours. Semin Oncol 1995; 22: 46-50 (suppl).
11. Vanhoefer, Wilke H, Weh H, et al. Weekly high dose 5-FU/folinic acid is active in chemotherapeutically pretreated gastric cancer. Ann Oncol 1994; 5: 850-1 (suppl).
12. Rougier P, Ducreux M, Mahjoubi M, et al. Efficacy of combined 5-FU and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994; 30A: 263-9.
13. Harstrick A, Vanhoefer U, Wilke H, et al. Interaction of Taxol with cisplatin, etoposide and 5-FU in human gastric carcinoma cell lines. Proc Am Ass Cancer Res 1994; 35: 332 (abstr).